Replies to post #47496 on Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

And for those who didn't look at the slides on the corporate presentation, it explains why we are targeting Colon Cancer,
Metastatic Squamous Histology Head and Neck Cancer and Metastatic Non-Small Cell Lung Cancer for Neo.

[mypekeispooped]

Thank you for that link, Dew. I also found this interesting: "In the study on which Hacohen and Wu collaborated, six people with melanoma received vaccines containing as many as 20 neoantigens each. Four of the patients were cancer-free two and a half years later. The tumours also disappeared in the other two patients, but only after treatment with a checkpoint inhibitor.

The other 2017 study, led by Ugur Sahin at Johannes Gutenberg University of Mainz in Germany, involved 13 people with melanoma, whose vaccines each contained a mix of 10 neoantigens. Nine of these people were cancer-free after a follow-up period of 12–23 months: eight had been given the vaccine alone and the other an additional checkpoint inhibitor."

Emphasis added.

[mm2k]

Dew, given all the positive news and preliminary results surrounding neoantigen vaccines, why is there not much excitement about the Advaxis implementation? Is there some perceived disadvantage of their approach, or is the only disadvantage that they have not yet started a phase I trial? Are the companies mentioned in this article further ahead in that sense?